Dermatology

413.6K Papers

Follow See full results

Article Dermatology

Clinically meaningful improvements in cutaneous lesions and quality of life measures in patients with atopic dermatitis with greater pruritus reductions after treatment with 60 mg nemolizumab subcutaneously every 4 weeks: subgroup analysis from a phase 3, randomized, controlled trial

Kenji Kabashima, Takayo Matsumura, Yoshiteru Hayakawa, Makoto Kawashima

Summary: The background data from the Japanese phase 3 study showed that nemolizumab in combination with topical treatments can reduce pruritus in atopic dermatitis. This post-hoc analysis found that improvements in pruritus were associated with improvements in eczema symptoms, sleep quality, and daily life.

JOURNAL OF DERMATOLOGICAL TREATMENT (2023)

添加到收藏夹

Article Dermatology

Upadacitinib for the treatment of concomitant psoriasis and atopic dermatitis: a case series

Luigi Gargiulo, Luciano Ibba, Giulia Pavia, Jessica Avagliano, Andrea Cortese, Antonio Costanzo, Alessandra Narcisi

Summary: This study reports the cases of four patients with overlapping features of both psoriasis and atopic dermatitis (AD). After being treated with several systemic drugs, including gold-standard treatments for both psoriasis and AD, they received upadacitinib 15 or 30 mg, achieving complete remission. Conclusion: To date, very limited data are available regarding the efficacy of upadacitinib in psoriasis.

JOURNAL OF DERMATOLOGICAL TREATMENT (2023)

添加到收藏夹

Article Dermatology

Maintained improvement in physician- and patient-reported outcomes with baricitinib in adults with moderate-to-severe atopic dermatitis who were treated for up to 104 weeks in a randomized trial

Jacob P. Thyssen, Thomas Werfel, Sebastien Barbarot, Hamish J. A. Hunter, Evangeline Pierce, Luna Sun, Lisa Cirri, Andrew S. Buchanan, Na Lu, Andreas Wollenberg

Summary: In the BREEZE-AD3 study, patients who received baricitinib 4 mg were observed for up to 104 weeks, showing sustained efficacy. Patients who down-titrated to 2 mg maintained improvements in skin conditions, itch, sleep, and quality of life.

JOURNAL OF DERMATOLOGICAL TREATMENT (2023)

添加到收藏夹

Article Dermatology

Dermal sensitization, safety, and tolerability of triple-combination clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15% gel from three clinical trials

Zoe D. Draelos, Emil A. Tanghetti, Leon H. Kircik, Neal Bhatia, Joshua A. Zeichner, Jeffrey L. Sugarman, Linda Stein Gold

Summary: Using a triple combination of clindamycin phosphate, benzoyl peroxide, and adapalene as acne treatment showed positive safety profile and good tolerability in healthy participants and those with moderate-to-severe acne, according to phase 1 and 2 studies.

JOURNAL OF DERMATOLOGICAL TREATMENT (2023)

添加到收藏夹

Letter Dermatology

Effectiveness of risankizumab in plaque psoriasis with involvement of difficultto-treat areas: a real-world experience from two referral centers

Diego Orsini, Luigi Gargiulo, Luciano Ibba, Ruggero Cascio Ingurgio, Mario Valenti, Chiara Perugini, Alessia Pacifico, Fabio S. Maramao, Pasquale Frascione, Antonio Costanzo, Alessandra Narcisi

JOURNAL OF DERMATOLOGICAL TREATMENT (2023)

添加到收藏夹

Article Dermatology

Years of dermatology experience and geographic region are associated with outlier performance of excision or destruction for nonmelanoma skin cancer

Brad R. Woodie, Scott A. Neltner, Annabella G. Pauley, Alan B. B. Fleischer Jr

Summary: A study on dermatologists performing procedures for nonmelanoma skin cancer (NMSC) found that less experienced doctors were more likely to choose excision as the treatment method. The choice of treatment method was also influenced by geographical region, with doctors in the South and Midwest more likely to choose excision, while doctors in the Northeast and Midwest more likely to choose destruction.

JOURNAL OF DERMATOLOGICAL TREATMENT (2023)

添加到收藏夹

Letter Dermatology

Exacerbation of psoriasis induced by lenalidomide in a patient with multiple myeloma

Guido Mioso, Laura Gnesotto, Irene Russo, Stefano Piaserico, Mauro Alaibac

JOURNAL OF DERMATOLOGICAL TREATMENT (2023)

添加到收藏夹

Article Dermatology

Treatment preferences among patients with mild-to-moderate atopic dermatitis

Kelley Myers, Jonathan I. Silverberg, Shreekant Parasuraman, Anna Pierce, Lawrence F. Eichenfield, Christine Poulos

Summary: The purpose of this study was to understand the treatment preferences of patients with mild-to-moderate atopic dermatitis (AD). A web-based discrete choice experiment (DCE) survey was conducted with 300 adults in the United States diagnosed with mild-to-moderate AD. Results showed that achieving clear or almost clear skin within 3-4 months of treatment was the most important attribute. Respondents preferred a topical cream applied twice daily over systemic treatments. Subgroup analysis revealed that respondents with lower disease burden were more likely to choose topical treatments and were less averse to treatment-related risks compared to those with higher disease burden.

JOURNAL OF DERMATOLOGICAL TREATMENT (2023)

添加到收藏夹

Article Dermatology

The differential effects of upadacitinib treatment on skin rashes of four anatomical sites in patients with atopic dermatitis

Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda

Summary: This study compared the therapeutic effects of Upadacitinib on different anatomical sites in patients with atopic dermatitis. The results showed that the lower limbs had the highest treatment responsiveness, while the trunk and head and neck had relatively lower responsiveness.

JOURNAL OF DERMATOLOGICAL TREATMENT (2023)

添加到收藏夹

Article Dermatology

A case of junctional epidermolysis bullosa intermediate with collagen XVII deficiency treated with dupilumab

Li Zhang, Shangshang Wang, Qinyi Chen, Leihong Xiang

Summary: We report a case of junctional epidermolysis bullosa that showed improvement with the use of Dupilumab.

JOURNAL OF DERMATOLOGICAL TREATMENT (2023)

添加到收藏夹

Article Dermatology

Treatment satisfaction of adult patients with moderate-to-severe atopic dermatitis treated with baricitinib in France, Germany, and the United Kingdom: results from a cross-sectional international patient survey

Matthias Augustin, Audrey Nosbaum, Thomas Werfel, Susanne Grond, Catherine Reed, Anastasia Lampropoulou, Nicole Tietz, Alan D. Irvine, Elisabeth Riedl

Summary: This study explored patient satisfaction with baricitinib, an oral Janus kinase inhibitor, in treating atopic dermatitis. The results showed that most patients were satisfied with the efficacy of baricitinib and its ability to control itch. Many patients also reduced or stopped the use of topical medications due to the effectiveness of baricitinib.

JOURNAL OF DERMATOLOGICAL TREATMENT (2023)

添加到收藏夹

Review Dermatology

A systematic review investigating at what proportion clinical images are shared in prospective randomized controlled trials involving patients with psoriasis and biological agents

Sam Polesie, Farzad Alinaghi, Alexander Egeberg

Summary: This study assessed the proportion of shared clinical images in psoriasis trials and found that patient images are seldom incorporated in clinical trial manuscripts. Including image material would strengthen patients' understanding of treatment effects.

JOURNAL OF DERMATOLOGICAL TREATMENT (2023)

添加到收藏夹

Article Dermatology

A center-based, ambulatory care concept for hidradenitis suppurativa improves patient outcomes and is also cost-effectiveness

Marcus Heise, Petra Staubach, Georgios Nikolakis, Lukas Schollenberger, Melanie Mauch, Marion Burckhardt, Marina Zamsheva, Alexandra Strobel, Gero Langer, Falk Bechara, Uwe Kirschner, Katharina Hennig, Christian Kunte, Matthias Goebeler, Maurizio Podda, Stephan Grabbe, Michael Schultheis

Summary: Hidradenitis suppurativa (HS) incurs substantial treatment costs, which increase with disease severity. A structured, multimodal form of care has been found to reduce costs in the treatment of HS compared to standard care.

JOURNAL OF DERMATOLOGICAL TREATMENT (2023)

添加到收藏夹

Letter Dermatology

Silicone-induced granulomas successfully treated with adalimumab

Francisco Javier de la Torre Gomar, Javier Gimeno Castillo, Pau Roses Gibert, Erika Iglesias Martinez, Maria Isabel Martinez Gonzalez

JOURNAL OF DERMATOLOGICAL TREATMENT (2023)

添加到收藏夹

Article Dermatology

Improvements in acne and skin oiliness with tazarotene 0.045% lotion in patients with oily skin

Emil A. Tanghetti, Joshua A. Zeichner, Michael Gold, Neil Sadick, Fran E. Cook-Bolden, Leon H. Kircik, Linda Stein Gold, Jonathan Weiss, Stephen K. Tyring, James Q. Del Rosso, Eric Guenin

Summary: This study aimed to evaluate the efficacy, changes in skin oiliness, and safety of Tazarotene 0.045% lotion in participants with moderate-to-severe acne and oily skin. The results showed that Tazarotene provided greater reductions in inflammatory/noninflammatory lesions and greater treatment success rates in participants with oily skin. Over two-thirds of polymeric lotion-treated participants reported subjective reductions in skin oiliness by week 12, with around a third reporting 'low/not' oily skin. Tazarotene's adverse event rates were similar to the overall population.

JOURNAL OF DERMATOLOGICAL TREATMENT (2023)

添加到收藏夹

Article Dermatology

Efficacy and safety of topical acetylcysteine combined with the use of an overcurvature-correcting device in patients with pincer nail deformity: a randomized, vehicle-controlled, investigator-blinded study

Masataka Saito, Akihiko Ikoma, Akira Fujikawa, Kazuaki Tanaka

Summary: The efficacy and safety of treatment with acetylcysteine (AC) gel added to an overcurvature-correcting device for hallux pincer nail were evaluated in this study. The optimal AC concentration was found to be 10%. The addition of AC gel to the device showed earlier and sustained reductions in transverse curvature compared to using the device alone.

JOURNAL OF DERMATOLOGICAL TREATMENT (2023)

添加到收藏夹

Article Dermatology

Identification of clinical predictors for dupilumab dose spacing in adults with atopic dermatitis: a real-world study

Andrea Chiricozzi, Giacomo Dal Bello, Niccolo Gori, Lucia Di Nardo, Donatella Schena, Giacomo Caldarola, Martina Maurelli, Clara De Simone, Giampiero Girolomoni, Ketty Peris

Summary: This study aimed to identify predictive factors for dose spacing or treatment withdrawal in patients receiving dupilumab for atopic dermatitis. The presence of non-cutaneous atopic manifestations, prurigo nodularis phenotype, and younger age at treatment initiation were confirmed as strong predictors. These findings contribute to defining the patient profile that can maintain therapeutic response after dose spacing or treatment withdrawal.

JOURNAL OF DERMATOLOGICAL TREATMENT (2023)

添加到收藏夹

Article Dermatology

A hyaluronic acid-based micro-filler improves superficial wrinkles and skin quality: a randomized prospective controlled multicenter study

Ferial Fanian, Jean-Jacques Deutsch, Marie Therese Bousquet, Sylvie Boisnic, Pierre Andre, Isabelle Catoni, Ghislaine Beilin, Christian Lemmel, Maryna Taieb, Marie Gomel-Toledano, Hanane Issa, Philippe Garcia

Summary: NCTF & REG;135HA is a bio-revitalizing solution containing hyaluronic acid that effectively reduces skin signs of aging. It significantly improves fine wrinkles and facial radiance, and increases skin hydration. The treatment is well-tolerated and superior to routine anti-aging cream alone.

JOURNAL OF DERMATOLOGICAL TREATMENT (2023)

添加到收藏夹

Letter Dermatology

Safety of anti-IL-23 drugs in patients with moderate-to-severe plaque psoriasis and previous tuberculosis infection: a monocentric retrospective study

Luciano Ibba, Luigi Gargiulo, Carlo Alberto Vignoli, Giovanni Fiorillo, Mario Valenti, Antonio Costanzo, Alessandra Narcisi

JOURNAL OF DERMATOLOGICAL TREATMENT (2023)

添加到收藏夹

Letter Dermatology

Pyoderma gangrenosum and Behcet's-like disease induced by secukinumab: a paradoxical drug reaction

Ceylan Avci, Guelfem Akin, Sevgi Akarsu, Banu Lebe

JOURNAL OF DERMATOLOGICAL TREATMENT (2023)

添加到收藏夹

«
1
2
3
4
5
»

See full results

Related Categories

Anesthesiology (212.5K) Audiology & Speech-Language Pathology (1.7K) Clinical Neurology (1.3M) Critical Care Medicine (338.4K) Dentistry, Oral Surgery & Medicine (340.8K) Emergency Medicine (142.9K) Endocrinology & Metabolism (751.7K) Gastroenterology & Hepatology (856.4K) Geriatrics & Gerontology (226.3K) Gerontology (158.2K) Health Care Sciences & Services (433.8K) Hematology (653.3K) Immunology (896.7K) Infectious Diseases (453.2K) Integrative & Complementary Medicine (99.8K) Medical Ethics (26.6K) Medical Informatics (100.5K) Medical Laboratory Technology (108K) Medicine, General & Internal (1.3M) Medicine, Legal (48.4K) Medicine, Research & Experimental (710K) Nursing (297.8K) Obstetrics & Gynecology (559.8K) Oncology (1.8M) Ophthalmology (452.2K) Orthopedics (359.5K) Otorhinolaryngology (166K) Pediatrics (655.3K) Peripheral Vascular Disease (595.7K) Pharmacology & Pharmacy (1.3M) Primary Health Care (59.2K) Psychiatry (755.1K) Radiology, Nuclear Medicine & Medical Imaging (799.4K) Rehabilitation (249.2K) Rheumatology (300.3K) Surgery (1.3M) Toxicology (333.1K) Transplantation (309.7K) Tropical Medicine (112.2K) Urology & Nephrology (567K) Veterinary Sciences (455.3K)

© Peeref 2019-2024. All rights reserved.